Mediwound Ltd
NASDAQ:MDWD

Watchlist Manager
Mediwound Ltd Logo
Mediwound Ltd
NASDAQ:MDWD
Watchlist
Price: 16.48 USD -1.67% Market Closed
Market Cap: 177.8m USD
Have any thoughts about
Mediwound Ltd?
Write Note

Operating Margin
Mediwound Ltd

-75.2%
Current
-52%
Average
6.8%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-75.2%
=
Operating Profit
-15.1m
/
Revenue
20.1m

Operating Margin Across Competitors

Country IL
Market Cap 177.8m USD
Operating Margin
-75%
Country JP
Market Cap 776 550.9T JPY
Operating Margin
-83%
Country US
Market Cap 710.5B USD
Operating Margin
35%
Country UK
Market Cap 440.4B GBP
Operating Margin
3%
Country DK
Market Cap 3.3T DKK
Operating Margin
44%
Country US
Market Cap 373.5B USD
Operating Margin
28%
Country US
Market Cap 251.1B USD
Operating Margin
34%
Country CH
Market Cap 202.7B CHF
Operating Margin
32%
Country CH
Market Cap 183.3B CHF
Operating Margin
31%
Country UK
Market Cap 162.4B GBP
Operating Margin
21%
Country IE
Market Cap 146B USD
Operating Margin
11%
No Stocks Found

Mediwound Ltd
Glance View

Market Cap
177.8m USD
Industry
Pharmaceuticals

MediWound Ltd. is a biopharmaceutical company engaging in the development, manufacture, and commercialization of products to address needs in the fields of severe burns, chronic wounds, and other hard-to-heal wounds. The firm focuses on developing, manufacturing and commercializing therapeutics products in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders and other indications. The firm's product, NexoBrid, is indicated for the removal of dead or damaged tissue, known as eschar, in adults with deep partial- and full-thickness thermal burns, also referred to as severe burns. The firm sells NexoBrid in Europe and Israel. NexoBrid is a topically-applied product that removes eschar in four hours without harming the surrounding healthy tissues. Its product, EscharEx, is a topical biological drug, which is being developed for debridement of chronic and other hard-to-heal wounds. NexoBrid and EscharEx are based on its proteolytic enzyme technology. The firm is also developing an injectable product based on its proteolytic enzyme technology for connective tissue pathologies and indications.

MDWD Intrinsic Value
10.47 USD
Overvaluation 36%
Intrinsic Value
Price

See Also

Discover More
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-75.2%
=
Operating Profit
-15.1m
/
Revenue
20.1m
What is the Operating Margin of Mediwound Ltd?

Based on Mediwound Ltd's most recent financial statements, the company has Operating Margin of -75.2%.